JP2009540842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009540842A5 JP2009540842A5 JP2009516907A JP2009516907A JP2009540842A5 JP 2009540842 A5 JP2009540842 A5 JP 2009540842A5 JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009516907 A JP2009516907 A JP 2009516907A JP 2009540842 A5 JP2009540842 A5 JP 2009540842A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mutated
- mutant
- immunotoxin
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 30
- 239000002596 immunotoxin Substances 0.000 claims 23
- 230000002637 immunotoxin Effects 0.000 claims 23
- 231100000608 immunotoxin Toxicity 0.000 claims 23
- 229940051026 immunotoxin Drugs 0.000 claims 23
- 239000003446 ligand Substances 0.000 claims 14
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 7
- 101150044134 US28 gene Proteins 0.000 claims 7
- 235000013922 glutamic acid Nutrition 0.000 claims 7
- 239000004220 glutamic acid Substances 0.000 claims 7
- 241000282414 Homo sapiens Species 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003053 toxin Substances 0.000 claims 5
- 231100000765 toxin Toxicity 0.000 claims 5
- 102000019034 Chemokines Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 108050005711 C Chemokine Proteins 0.000 claims 3
- 102000017483 C chemokine Human genes 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 claims 1
- -1 Buganin Proteins 0.000 claims 1
- 102000001902 CC Chemokines Human genes 0.000 claims 1
- 108010040471 CC Chemokines Proteins 0.000 claims 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 claims 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 claims 1
- 108050006947 CXC Chemokine Proteins 0.000 claims 1
- 102000019388 CXC chemokine Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 101150030083 PE38 gene Proteins 0.000 claims 1
- 241000282405 Pongo abelii Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 108010084592 Saporins Proteins 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 108010049223 bryodin Proteins 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 claims 1
- 210000005265 lung cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- 244000144977 poultry Species 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200600900 | 2006-07-03 | ||
| PCT/DK2007/050082 WO2008003327A2 (en) | 2006-07-03 | 2007-07-03 | Immunotoxins for the treatment of diseases related to cmv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009540842A JP2009540842A (ja) | 2009-11-26 |
| JP2009540842A5 true JP2009540842A5 (enExample) | 2010-08-19 |
Family
ID=38739380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009516907A Pending JP2009540842A (ja) | 2006-07-03 | 2007-07-03 | Cmv感染に関連する疾患の治療のための免疫毒素 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8592554B2 (enExample) |
| EP (1) | EP2038302B1 (enExample) |
| JP (1) | JP2009540842A (enExample) |
| CA (1) | CA2656992A1 (enExample) |
| WO (1) | WO2008003327A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010070394A1 (en) * | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| CN114206944A (zh) * | 2019-07-12 | 2022-03-18 | 哥本哈根大学 | 用于治疗cmv感染相关疾病的融合毒素蛋白 |
| US20220324947A1 (en) * | 2019-08-05 | 2022-10-13 | Stichting Vu | Identification and Elimination of HCMV-Infected Cells |
| MX2022002628A (es) * | 2019-09-03 | 2022-03-25 | Synklino Aps | Proteinas de fusion y usos de las mismas. |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| CA2240409C (en) * | 1996-01-24 | 2011-03-22 | Schering Corporation | Mammalian cx3c chemokine genes |
| CA2301846A1 (en) * | 1997-09-04 | 1999-03-11 | Gryphon Sciences | Modular protein libraries and methods of preparation |
| DE69934337T2 (de) | 1998-07-22 | 2007-05-24 | Osprey Pharmaceuticals Ltd., Calgary | Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung |
| CA2341361A1 (en) * | 1998-08-31 | 2000-03-09 | Oregon Health Sciences University | Prevention of cell migration initiation with cmv us28 receptor antagonists |
| EP1272512A4 (en) | 2000-03-23 | 2003-05-07 | Phylomed Corp | IMMUNOKIN COMPOSITION AND METHOD |
| US20020192212A1 (en) * | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| US20050136033A9 (en) | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
| CN1768862A (zh) * | 2004-10-26 | 2006-05-10 | 北京诺思兰德生物技术有限责任公司 | 一类能与表达GnRH受体的癌细胞特异结合且用锝-99m标记的蛋白 |
-
2007
- 2007-07-03 WO PCT/DK2007/050082 patent/WO2008003327A2/en not_active Ceased
- 2007-07-03 CA CA002656992A patent/CA2656992A1/en not_active Abandoned
- 2007-07-03 JP JP2009516907A patent/JP2009540842A/ja active Pending
- 2007-07-03 EP EP07764502A patent/EP2038302B1/en not_active Not-in-force
- 2007-07-03 US US12/306,395 patent/US8592554B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW496870B (en) | Compositions methods for stimulating megakaryocyte growth and differentiation | |
| TWI802396B (zh) | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 | |
| JP6345216B2 (ja) | オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途 | |
| JP6499333B2 (ja) | オキシントモジュリン誘導体を含む高脂血症の治療のための組成物 | |
| KR101895047B1 (ko) | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 | |
| JP2009540842A5 (enExample) | ||
| ES2319827T3 (es) | Proteinas quimericas especificas del receptor il-13, y sus usos. | |
| US10188703B2 (en) | Method for treating diabetes mellitus by a composition comprising insulin and a GLP-1/glucagon dual agonist | |
| TWI423813B (zh) | 使用免疫球蛋白片段之長效β干擾素製劑 | |
| CN1665933B (zh) | 用于治疗肿瘤的免疫缀合物 | |
| TWI795443B (zh) | Glp-2衍生物之長效接合物 | |
| JP2007500236A5 (enExample) | ||
| EP3068797A1 (en) | Epha3 and multi-valent targeting of tumors | |
| JP2024528496A (ja) | ウロキナーゼ型プラスミノーゲン活性化因子受容体関連タンパク質(uparap)を標的とするヒト化抗体を含む、抗体薬物複合体 | |
| CN110092837B (zh) | Uti融合蛋白 | |
| JP2001526242A5 (enExample) | ||
| KR101746686B1 (ko) | 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체 | |
| JP2022513209A (ja) | オリゴペプチドを有効成分として含むがんの予防または治療用薬学的組成物 | |
| US11752216B2 (en) | Insulin analog complex with reduced affinity for insulin receptor and use thereof | |
| JP7668785B2 (ja) | 融合タンパク質およびその使用 | |
| CN117964777A (zh) | 一种接近天然分子的多肽融合分子 | |
| WO2010074082A1 (ja) | バソヒビン修飾体 | |
| CN113329752A (zh) | 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法 | |
| Nemati et al. | The Types and Applications of Peptibodies | |
| RU2024113218A (ru) | Конъюгат антитело против cd37-лекарственное средство |